ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2654

Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes

Yen Chen1, Mary Alore2, Dinesh Khanna1 and Susan Murphy3, 1University of Michigan, Ann Arbor, MI, 2Self-employed, TROY, MI, 3University of Michigan, Plymouth, MI

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Cognitive dysfunction, Fatigue, mood, Rehabilitation, Scleroderma, Systemic

Session Information

Date: Monday, November 18, 2024

Title: Abstracts: ARP Interprofessional II: Psychology & Practice

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), often significantly impairing their work and daily activities and exacerbating other symptoms such as pain, fatigue, and depressed mood. Cognitive dysfunction could also make managing SSc more challenging and reduce the effectiveness of self-management interventions. Cognitive rehabilitation interventions have been shown to improve cognitive function, alleviate symptoms, and enhance disease self-management. We adapted and tested one such intervention, specifically tailored for people with SSc, into an 8-week online format with a co-facilitator who has SSc. We examined the acceptability, feasibility, and impact of health-related outcomes of this intervention.

Methods: We recruited participants from a SSc registry who perceived moderate to severe cognitive dysfunction (≥ 10 on the Perceived Deficits Questionnaire). Eight online educational sessions were combined with the practice of an evidence-based brain-training program. Our tailored online intervention addressed the travel and physical constraints people with SSc face. Online educational sessions were co-led by an individual with SSc to provide unique patient perspectives and offer peer support. We assessed cognitive function using the Trail Making Test (TMT) A (attention), TMT B (mental flexibility), the Stroop Color-Word test (executive function), Immediate Recall (memory), and Delayed Recall (memory). Additionally, PROMIS measures of perceived cognitive function, pain, fatigue, and depressed mood, as well as the Compensatory Cognitive Strategies Scale and Patient Activation Measure (disease self-management) were assessed. Outcomes were evaluated at baseline and week 8 (post-intervention). Paired t-tests were used to examine pre- and post-test differences. The significance level was set at 0.05. A post-intervention feedback questionnaire and attendance records were used to evaluate the acceptability and feasibility of the intervention.

Results: Ten participants were enrolled (mean age = 53 ± 13 years; 5 diffuse SSc subtype) (Table 1). Although most cognitive function test scores did show significant changes, attention improved significantly at week 8 (t (8) = -2.6, p = 0.03). Additionally, perceived cognitive function and fatigue showed significant improvements at week 8 (t [9] = −2.4, p = 0.04 and (t [9] = 2.6, p = 0.03, respectively) (Table 2). All participants rated the program as either good or excellent. They reported learning new cognitive strategies or lifestyle modifications to improve their brain function, with 90% indicating they would continue using these strategies. Ninety percent of the participants had perfect attendance or missed only one online session.

Conclusion: Cognitive dysfunction is a prevalent issue in SSc. Cognitive rehabilitation interventions, such as the one piloted in this study, hold promise for improving attention, self-reported cognitive function, and reducing fatigue among people with SSc and may also benefit those with other chronic conditions. Although our pilot study was well-received by participants and demonstrated feasibility, a larger randomized trial is needed to test its efficacy.

Supporting image 1

Table 1. Sample characteristics (N = 10)

Supporting image 2

Table 2. Pre- and post-intervention scores in key outcome measures (N = 10)


Disclosures: Y. Chen: None; M. Alore: None; D. Khanna: AbbVie/Abbott, 2, Amgen, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Certa Therapeutics, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, MDI Therapeutics, 8, Merck/MSD, 2, Novartis, 2, Zura Bio, 2; S. Murphy: None.

To cite this abstract in AMA style:

Chen Y, Alore M, Khanna D, Murphy S. Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/adapting-and-testing-a-cognitive-rehabilitation-intervention-tailored-for-people-with-systemic-sclerosis-acceptability-feasibility-impact-on-health-related-outcomes/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adapting-and-testing-a-cognitive-rehabilitation-intervention-tailored-for-people-with-systemic-sclerosis-acceptability-feasibility-impact-on-health-related-outcomes/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology